Extension Study for Patients Who Completed GENA-05 (NuProtect)- to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII
Phase of Trial: Phase III
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs Simoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Pharmacodynamics; Registrational
- Sponsors Octapharma
- 28 Feb 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 26 Feb 2019 Status changed from active, no longer recruiting to completed.
- 17 Apr 2018 Planned End Date changed from 1 Apr 2018 to 31 Dec 2018.